Sentence examples similar to maintain cost effectiveness from inspiring English sources

To maintain cost-effectiveness parity with ART alone, a supplement needed to cost $10.99 per quarter and confer a 20% reduction in both 6-month mortality and loss to follow-up among BMI <16.0 kg/m patients.

In a population of HIV-infected malnourished adults in Zambia, the minimum proportional reductions in mortality and loss to follow-up necessary for a combined nutrition support and ART treatment program to maintain cost-effectiveness parity with ART alone appear to be reasonable endpoints for prospective studies utilizing several candidate supplements.

We used Markov models incorporating historical data and program-wide estimates of treatment costs and health benefits from the Zambian national ART program to estimate the improvements in 6-month survival and program retention among malnourished adults necessary for a combined nutrition support and ART treatment program to maintain cost-effectiveness parity with ART treatment alone.

In this analysis, we use cost estimates from a recent analysis of 45 ART clinics in Zambia, in combination with health outcomes data on over 19,000 patients, to model the minimum improvements in survival and program retention necessary for a hypothetical combined nutrition support and ART treatment program to maintain cost-effectiveness parity with ART treatment alone [ 16].

Our analysis of the effects of a nutrition supplementation program for HIV-infected, low BMI adults starting ART in a resource-constrained setting incorporated historical health outcomes data with program-wide cost data to define minimum improvements in survival and program retention necessary to maintain cost-effectiveness parity with ART treatment alone.

To an important extent, this is likely to reflect different strategies for balancing concerns about assuring adequate take-up while maintaining cost-effectiveness.

40 To overcome some of the challenges, while maintaining cost-effectiveness, the use of a self-directed approach has been proposed.

Research is needed to identify the optimum balance between self-delivered and fully guided treatments in order to enhance acceptability while maintaining cost-effectiveness.

These findings are robust for wide differences in key disease and test parameters, such as if IGRA test costs are three times TST costs, while maintaining cost-effectiveness at the lower end of the £20 000–£30 000 NICE band.

Nevertheless, our findings suggest that initial risk stratification using CIMT may allow selective referral of asymptomatic patients with type 2 diabetes requiring further imaging and intensification of therapy, thereby improving patient outcome while maintaining cost-effectiveness.

We discuss the innovative nature of this trial and the challenges related to choice of patient population, maintaining masking, cost effectiveness, ethical considerations, measuring adherence, and placebo development and testing.